- Conditions
- Metastatic Breast Cancer
- Interventions
- fulvestrant, anastrozole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years to 100 Years · Female only
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 5
- States / cities
- Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–44
of 44
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hormone Receptor Positive Breast Cancer
- Interventions
- faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 12
- States / cities
- Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more
- Conditions
- Incident Breast Cancer
- Interventions
- tea capsule
- Dietary Supplement
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Estrogen-receptor Positive Invasive Metastatic Breast Cancer
- Interventions
- Ruxolitinib, Exemestane
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ER+ and AR+ Breast Cancer
- Interventions
- GTx-024
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Fort Lauderdale, Florida • Boston, Massachusetts • Billings, Montana + 1 more
- Conditions
- Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- sorafenib tosylate, anastrozole
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer
- Interventions
- anastrozole, gefitinib
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Her2 Negative Breast Cancer Patients
- Interventions
- MM-121, Placebo, Exemestane
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Anaheim, California + 13 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- fulvestrant, anastrozole
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 856
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
- Conditions
- Breast Cancer
- Interventions
- letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, tamoxifen citrate, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 3,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 724
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more
- Conditions
- Osteoporosis
- Interventions
- Apomine
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • West Haverstraw, New York
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Arthralgia, Postmenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Dietary Intervention, Exercise Intervention, Questionnaire Administration
- Dietary Supplement · Behavioral · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, BKM120, BKM120 matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
- Conditions
- Breast Cancer, Endometrial Cancer
- Interventions
- medroxyprogesterone, tamoxifen citrate, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 122
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant, BKM120, BKM120 matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
- Conditions
- Breast Neoplasms
- Interventions
- CP-751,871, exemestane, Fulvestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 33
- States / cities
- La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
- Interventions
- testosterone, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 528
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- BKM120, Fulvestrant, biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Postmenopausal Female Patients, Vasomotor Symptoms, Menopausal Hormone Therapy
- Interventions
- Moderate Intensity Exercise (MIE), High intensity exercise (HIE), Control (No exercise)
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia